The consequences of Th17 plasticity in arthritis were initially unclear, as the switch from IL-17 to IFNγ seemed unlikely to drive significant pathology given that administration of recombinant IFNγ to patients with rheumatoid arthritis has no adverse consequences (18). This evidence concerns the gene IL17A and Arthritis.